MarketResearchReports.Biz has announced addition of new report “Rytary/IPX066 (Parkinsons Disease) – Forecast And Market Analysis To 2022” to its database.
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
View Full Report at http://www.marketresearchreports.biz/analysis/197524
Rytary, also known as IPX066, is a levodopa-based product for the treatment of early and advanced Parkinsons disease. It was developed by the generics manufacturer Impax Laboratories and contains a capsule with different-sized beads that dissolve at different rates, releasing a 1:4 ratio of carbidopa: levodopa.
– Overview of Parkinsons disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on Rytary including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for Rytary for the top six countries from 2012 to 2022.
– Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Download Sample Copy of Report at http://www.marketresearchreports.biz/sample/sample/197524
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Parkinsons disease
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of Rytary performance
– Obtain sales forecast for Rytary from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Disease Management 21
4.1 Overview 21
4.1.1 Diagnosis – The UK Brain Bank Criteria 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.2 Treatment Synopsis 25
4.2.1 Dopaminergic Therapy Classes 25
4.2.2 Treatment of Parkinsons Disease by Stage 27
4.2.3 Other Treatment Options 30
4.3 Parkinsons Disease Assessment Scales 30
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 31
4.3.2 Hoehn and Yahr Clinical Staging 33
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Browse Latest Industry Press Release http://www.marketresearchreports.biz/pressreleases
90 State Street, Suite 700
Albany, NY 12207
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz